Hybrid coronary revascularization versus off-pump coronary artery bypass grafting for treatment of multivessel coronary artery diseases
- VernacularTitle:杂交技术与非体外循环冠状动脉旁路移植术治疗冠状动脉多支血管病变的对比研究
- Author:
Wei SHENG
1
;
Liyue ZHAO
1
;
Tianyi WANG
1
;
Zhaozhuo NIU
1
;
Wenfeng ZHANG
1
;
Jiantao WU
1
;
Haoyou LI
1
;
Haiqin YANG
2
Author Information
1. Department of Cardiovascular Surgery, Qingdao Municipal Hospital, Medical College of Qingdao University, Qingdao, 266071, Shandong, P.R.China
2. Department of Mental Intervention, Qingdao Preferential Hospital, Qingdao, 266071, Shandong, P.R.China
- Publication Type:Journal Article
- Keywords:
Hybrid technique;
coronary artery bypass grafting;
minimally invasive;
percutaneous coronary intervention;
surgery
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(07):801-805
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the feasibility and safety of hybrid coronary revascularization (HCR) in patients with multivessel coronary artery disease (MVCAD). Methods A total of 50 patients with MVCAD who underwent HCR technique in our heart center from May 2016 to April 2019 were included in this study (a HCR group), including 38 patients who underwent two-stage HCR and 12 patients one-stop HCR. There were 39 males and 11 females, with an average age of 62.4 (46-82) years. Another 482 patients who underwent conventional median incision under off-pump coronary artery bypass grafting (OPCAB) at the same period were selected as control (an OPCAB group), including 392 males and 90 females, with an average age of 64.2 (48-84) years. The safety and feasibility of HCR were evaluated and compared with conventional OPCAB technique. Results There was no perioperative death in both groups. Compared with the OPCAB, HCR was associated with shorter operation time, less chest tube drainage, lower requirement of blood transfusion, shorter mechanical ventilation time and shorter postoperative intensive care unit (ICU) stay (P<0.05). There was no statistical difference in the incidence of major adverse cardiac or cerebrovascular events during the follow-up of 6 to 36 months between the two groups. Conclusion HCR provides favorable short and mid-term outcomes for selected patients with MVCAD compared with conventional OPCAB.
